Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future.
Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment.
PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Sonia Waraich Source Type: news
More News: American Health | Clinical Trials | Gene Therapy | Genetics | Health Management | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Study